Opioid analgesics for rheumatoid arthritis pain

JAMA

Volumn 309, Issue 5, 2013, Pages 485-486

  Whittle, Samuel L ^a   Richards, Bethan L ^b   Buchbinder, Rachelle ^c  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CODEINE; DEXTROPROPOXYPHENE; MORPHINE; NARCOTIC ANALGESIC AGENT; PARACETAMOL; PENTAZOCINE; PLACEBO; TILIDINE; TRAMADOL;

ANALGESIA; ARTHRALGIA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 84873277283     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.193412     Document Type: Note

References (7)

1. Nelson LS, Perrone J. Curbing the opioid epidemic in the United States: the risk evaluation and mitigation strategy (REMS). JAMA. 2012;308(5):457-458.
2. Heiberg T, Kvien TK. Preferences for improved health examined in 1,024 patients with rheumatoid arthritis: pain has highest priority. Arthritis Rheum. 2002;47(4):391-397.
3. Grijalva CG, Chung CP, Stein CM, Mitchel EF Jr, Griffin MR. Changing patterns of medication use in patients with rheumatoid arthritis in a Medicaid population. Rheumatology (Oxford). 2008;47(7):1061-1064.
4. Whittle SL, Richards BL, Husni E, Buchbinder R. Opioid therapy for treating rheumatoid arthritis pain. Cochrane Database Syst Rev. 2011;(11):CD003113. doi: 10.1002/14651858.CD003113.pub3.
5. Boada JN, Boada C, García-Sáiz M, García M, Fernández E, Gómez E. Net efficacy adjusted for risk (NEAR): a simple procedure for measuring risk: benefit balance. PLoS One. 2008;3(10):e3580. doi: 10.1371/journal.pone.0003580.
6. Whittle SL, Colebatch AN, Buchbinder R, et al. Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative. Rheumatology (Oxford). 2012;51(8):1416-1425.
7. Moore RA, Derry S, McQuay HJ, et al; ACTINPAIN writing group of the IASP Special Interest Group (SIG) on Systematic Reviews in Pain Relief. Clinical effectiveness: an approach to clinical trial design more relevant to clinical practice, acknowledging the importance of individual differences. Pain. 2010;149(2):173-176.